Please enable JS

ARTICLES & TESTIMONIALS

FILTER BY TYPE

Most Recent

Categories

ARCHIVES

Amgen Just Slashed Its Price of the Cholesterol-Lowering Drug Repatha. So What Does This Mean for You?

Oct 29// PCSK9i

You may have heard that Amgen, which manufactures the cholesterol-lowering drug evolocumab (Repatha), just announced it is lowering the list price of the drug by about 60 percent to $5,850 per year from its original list price of $14,523. The company says that the goal of the price drop is to help lower patients’ copays, […]

READ MORE

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia

Dec 26// PCSK9i

A study found that Repatha® (evolocumab) significantly reduced LDL cholesterol in patients with and without elevated triglycerides compared to placebo and Zetia® (ezetimibe). Learn more about the differences among LDL, HDL and triglycerides from the American Heart Association. Read more.

READ MORE

NEJM Study of Evolocumab Efficacy in Lowering LDL Cholesterol

Dec 26// PCSK9i

A study published in the New England Journal of Medicine found that Repatha® (evolocumab) reduced LDL cholesterol levels by 61 percent from pretreatment levels, and this reduction was sustained through 48 weeks. Patients taking evolocumab also showed a reduction in the rate of cardiovascular events. Learn more about the differences among LDL, HDL and triglycerides […]

READ MORE

Study Shows Safety and Efficacy of Anti-PCSK9 Antibodies in Lowering LDL Cholesterol

Dec 26// PCSK9i

A study published in BMC Medicine found that the anti-PCSK9 antibodies Repatha® (evolocumab) and Praluent® (alirocumab) reduced the LDL (bad) cholesterol level by over 50 percent, increased the HDL (good) cholesterol level, and resulted in favorable changes in other lipids. As some patients cannot tolerate statins, there is a need for alternative treatments that lower […]

READ MORE